Abivax to Showcase Nine Obefazimod Abstracts Including Dual Anti-Fibrotic Data at DDW
Abivax will present nine scientific abstracts on obefazimod at Digestive Disease Week May 2-5, showcasing Phase 3 ABTECT program data on efficacy, safety and patient-reported outcomes in moderately to severely active ulcerative colitis. Presentations also include preclinical models demonstrating obefazimod’s dual anti-inflammatory and anti-fibrotic activity.
1. Presentation Details
Abivax will unveil nine abstracts on obefazimod at Digestive Disease Week 2026 in Chicago from May 2 to 5, covering clinical and preclinical findings.
2. Phase 3 ABTECT Highlights
Abstracts from ABTECT-1 and ABTECT-2 include efficacy, safety, histologic and endoscopic outcomes and subgroup analyses in patients with moderately to severely active ulcerative colitis.
3. Patient-Reported Outcomes
Data will show early symptomatic improvements in fatigue and quality-of-life metrics from pooled induction trial results.
4. Preclinical Anti-Fibrotic Findings
Two presentations describe obefazimod’s anti-fibrotic effects in murine fibrosis models and its modulation of inflammatory cytokines and mir-124 expression in human tissues.